Placebo Optimization of the Presurgical Long-term Video-EEG Monitoring

NCT ID: NCT06383689

Last Updated: 2024-06-10

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-13
• Study Completion Date: 2026-12-31

Brief Summary

The notion of genuine placebo effects on epileptic seizure events (i.e., effects beyond methodological study artifacts) is incompatible with the standard model of epilepsy seizure genesis. In this single-blind controlled study, the effectiveness of a covered placebo on (1) the timing of the occurrence of a first epileptic seizure ("seizure pill") versus (2) the subjective well-being ("comfort pill") during pre-surgical video-EEG monitoring will be examined. It is hypothesized that a placebo effect on subjective well-being can be demonstrated, but that epileptic seizure events are not influenced by placebo.

Detailed Description

Patients undergoing long-term video-EEG monitoring for the purpose of pre-operative epilepsy diagnostics will be invited to participate in the study. Patients will be pseudo-randomized into three study conditions (in blocks of six). The study participants will take a placebo pill designated either as a "seizure pill" (Condition PCB-S) or a "comfort pill" (PCB-W) in addition to their regular medication in the morning and evening, or not receive any additional placebo medication (No-PCB).

Both the "seizure pill" and the "comfort pill" are commercially available, ingredient-free placebo pills (P-pills blue Lichtenstein, produced by Winthrop Pharmaceuticals). No further details about the composition of the pill will be provided; information about the ingredients of the respective pill will be provided after the end of the entire study. Depending on randomization, study participants will be informed that this pill is expected to (1) either facilitate/accelerate the occurrence of epileptic seizures (PCB-S) (thereby shortening the required time for video-EEG monitoring), or (2) to lead to a more stable/improved emotional well-being during the stay in the V-EEG (PCB-W) or (3) will not receive a pill but are asked to fill-in questionnaires and diaries like the other patients.Start of the V-EEG will be documented as the starting point for latency measurement for the occurrence of a first epileptic seizure. The patients will be pseudo-randomized into the three study conditions: Out of every 6 patients, 2 will be assigned to each of the three study conditions. Patients in both active study conditions will receive the first pill at the start of the V-EEG. After that, study participants will receive the respective "pill" morning and evening in addition to their other medications, however, visibly separated from them and clearly marked as study medication. All participants, including controls, will keep a seizure diary during the V-EEG. In addition, they will fill-in a newly constructed ad-hoc questionnaire at the beginning and after the V-EEG. Finally, all patients will be asked twice daily (around 9 AM and around 6 PM) about their overall emotional well-being using a visual analogue scale (VAS; 0 very bad ... 100 extremely good). The highly standardized clinical procedures of presurgical evaluation are in no way affected by the study. In particular, anti-seizure medications for all patients will be tapered off following exactly the same schedule without any influence from the study; the medication will be precisely documented.

Conditions

Symptomatic Epilepsy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Seizure placebo pill (PCB-S)

Patients assigned to this condition receive a covered placebo pill (1-0-1) on a daily basis with the indication of possible acceleration of the occurrence of an epileptic seizure (which then allows to conclude V-EEG monitoring faster)

Group Type: EXPERIMENTAL

Seizure placebo pill

Intervention Type: OTHER

patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG

Well-being placebo pill (PCB-W)

Patients assigned to this condition receive a covered placebo pill (1-0-1) on a daily basis with the indication of possible improvement of emotional well-being during the demanding V-EEG monitoring procedure

Group Type: EXPERIMENTAL

Well-being placebo pill

Intervention Type: OTHER

patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG

No pill (control)

Patients assigned to this condition receive no study pill but are asked to fill-in all questionnaires and diaries like patients in the two active arms

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Seizure placebo pill

patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible acceleration of seizure occurrence during presurgical video-EEG

Intervention Type: OTHER

Well-being placebo pill

patients in this study arm receive a covered placebo pill on a daily basis (1-0-1) with the indication of possible improvement of emotional well-being during video-EEG

Intervention Type: OTHER

Other Intervention Names

PCB-S; PCB-W

Eligibility Criteria

Inclusion Criteria

• eligibility for presurgical epilepsy diagnostics

Exclusion Criteria

• legal guardian
• lack of consent or lack of capability to provide informed consent

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Bonn

OTHER

Sponsor Role: lead

Responsible Party

Christian Hoppe

Senior Researcher (Clinical Neuropsychologist)

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Rainer Surges, Prof.

Role: PRINCIPAL_INVESTIGATOR

Department of Epileptology, University Hospital Bonn, Germany

Locations

Department of Epileptology, University Hospital Bonn

Bonn, North Rhine-Westphalia, Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Rainer Surges, Prof.

Role: CONTACT

rainer.surges@ukbonn.de

+49 228 287-15727

Christian Hoppe, PD Dr.

Role: CONTACT

christian.hoppe@ukbonn.de

+49 228 287-16172

Facility Contacts

Rainer Surges, Prof.

Role: primary

rainer.surges@ukbonn.de

+49 228 287-15727

Christian Hoppe, PD Dr.

Role: backup

christian.hoppe@ukbonn.de

+49 228 287-16172

Other Identifiers

Az. 297/23-EP

Identifier Type: -

Identifier Source: org_study_id